of Humatrope (somatropin) in a Patient With COVID-19
is an infectious respiratory disease caused by SARS-CoV-2, previously
referred to as "2019 novel coronavirus."1
has not studied the use of Humatrope in patients with COVID-19 nor in
patients at risk of contracting COVID-19.
hormone should not be initiated to treat patients with acute critical
illness due to complications following open heart or abdominal
surgery, multiple accidental trauma, or to patients having acute
respiratory failure. 2
has been reported in somatropin clinical trials and post-marketing
spontaneous reports in 1%-10% of adults.2
should use their clinical judgment in determining the most
appropriate approach in treating a patient with Humatrope who has
confirmed or suspected COVID-19.
Disease Resources for COVID-19
current information on COVID-19, please refer to
Naming the coronavirus disease (COVID-19) and the virus that causes
it. World Health Organization. Accessed March 17, 2020.
Humatrope [summary of product characteristics]. Eli Lilly and
Company Limited, Hampshire.
Coronavirus disease (COVID-19) outbreak. European web page of the
World Health Organization. Accessed March 20, 2020.
COVID-19 INFORMATION FOR CHILDREN AND ADOLESCENTS LIVING WITH
ENDOCRINE CONDITIONS, INCLUDING TYPE 1 DIABETES MELLITUS
Accessed March 26, 2020
COVID-19. European Centre for Disease Prevention and Control.
Accessed March 20, 2020.
= coronavirus disease 2019
= European Centre for Disease Prevention and Control
= European Society for Paediatric Endocrinology
WHO = World Health Organization (European regional office)
= Eli Lilly and Company
= severe acute respiratory syndrome coronavirus 2